Emerging Trends in Leptospirosis: Advancements in Diagnosis, Treatment, and Prevention Strategies

T. Murugalakshmi[1], R. Akila[2], R. Gopinathan[3] and J. Suriakumar[3*]

[1]*Department of Pharmacology, Government Medical College, Dindigul, Tamil Nadu, India.*
[2]*Departement of Pathology, Thanjavur Medical College, Thanjavur, Tamil Nadu, India.*
[3]*Department of Microbiology, Government Medical College, Dindigul, Tamil Nadu, India.*

[*]***Corresponding author:*** *J. Suriakumar*
**Department of Microbiology, Government Medical College, Dindigul, Tamil Nadu, India.*

KEYWORDS	ABSTRACT
Leptospirosis, *Leptospira* species, Molecular diagnostics, Antibiotic therapy, Prevention strategies.	Leptospirosis, a zoonotic bacterial disease caused by Leptospira species, remains a significant public health concern, particularly in tropical and subtropical regions. Transmission primarily occurs through the urine of infected animals, including rodents and livestock. This review explores the emerging trends in the diagnosis, treatment, and prevention of leptospirosis. Advances in molecular diagnostics, such as polymerase chain reaction (PCR) and real-time qPCR, have improved early detection and accuracy. Serological tests like ELISA and rapid lateral flow assays offer timely diagnosis in endemic areas. Treatment strategies focus on antibiotic therapy, but research into immunotherapy, vaccines, and combination therapies is progressing to address severe cases. Preventive measures, including rodent control, vaccination of high-risk populations, and public health education, are key to mitigating the disease's spread. By integrating novel diagnostic tools, therapies, and comprehensive prevention strategies, the global burden of leptospirosis can be reduced, improving outcomes and public health safety.

Introduction

Leptospirosis is a bacterial zoonotic illness caused by spirochetes of the Leptospira species. It is primarily spread through contact with infected animals' urine, such as rats, livestock, and wildlife. Infection is generally acquired through direct contact with polluted water, soil, or food, or through open wounds exposed to these contaminated sources [1]. Leptospirosis is a major public health concern, especially in tropical and subtropical areas where the environmental circumstances encourage the survival and spread of Leptospira bacteria. The disease is widely dispersed worldwide, with the highest occurrence in areas with poor sanitation, limited infrastructure, and frequent flooding. Urbanization, agricultural development, and climate change have all increased the danger of leptospirosis transmission, especially in highly populated areas [2]. The clinical presentation of leptospirosis varies greatly, ranging from mild, flu-like symptoms to severe, life-threatening indications. Mild cases may cause fever, headache, muscle discomfort, and vomiting, which can be confused for other infectious disorders. Severe leptospirosis, often known as Weil's illness, is marked by jaundice, renal failure, haemorrhages, and, in some cases, respiratory distress syndrome (ARDS), meningitis, or multi-organ failure [3]. Severe forms of leptospirosis have a significant death rate if not recognized and treated very once. The large range of possible symptoms makes it difficult to detect in the early stages, resulting in delayed treatment and increased consequences [4]. Despite its worldwide prevalence, leptospirosis is nevertheless underreported and underdiagnosed, owing to a lack of timely, reliable diagnostic techniques, particularly in low-resource settings. Furthermore, the difficulty of accurate and timely diagnosis is exacerbated by the fact that symptoms can mimic those of many other infectious diseases, including dengue, malaria, and typhoid fever. Improving diagnostic technologies that can rapidly and effectively detect Leptospira in patients is crucial for prompt intervention and successful treatment results [5].

Leptospirosis is typically treated with antibiotics, such as doxycycline or penicillin, which are helpful in mild to moderate cases. However, severe instances frequently necessitate more invasive interventions, such as intravenous antibiotics and supportive care like dialysis for renal failure and mechanical ventilation for respiratory distress [6]. Unfortunately, there is no specific antiviral or vaccine treatment for human leptospirosis, and the vaccinations that are currently available are mostly designed to minimize the reservoir of illness in animals, notably livestock [7]. Leptospirosis prevention focuses mostly on avoiding human exposure to polluted surroundings and animals. Public health measures focus on increasing sanitation and hygiene, reducing rat populations, and educating people about the risks of exposure. To lower the risk of infection in at-risk populations such as agricultural labourers and military people, personal protective equipment and doxycycline chemoprophylaxis have been utilized. Despite these precautions, leptospirosis remains a severe problem in many regions of the world [8]. Recent advances in leptospirosis research,

particularly in diagnostic technology, therapeutic tactics, and preventive measures, provide new hope for the disease's treatment. These advances are likely to alleviate many of the present issues in leptospirosis management while also improving outcomes for affected patients. One of the most promising advancements in diagnosis is the advancement of molecular techniques like polymerase chain reaction (PCR) and real-time PCR, which can detect Leptospira DNA in clinical samples with great sensitivity and specificity [9]. Furthermore, novel point-of-care diagnostic techniques, such as lateral flow immunoassays, are being developed to provide rapid and reliable results in field settings, particularly in resource-constrained locations where leptospirosis is most prevalent [10]. In terms of treatment, researchers are investigating the possible use of novel antimicrobial drugs and immunotherapy to supplement traditional antibiotic therapy, particularly in severe forms of the condition. The goal of studies on monoclonal antibodies, immune modulators, and other adjuvant medicines is to enhance patient outcomes and reduce problems associated with severe leptospirosis. Another promising area of research is the development of human vaccines, which, if effective, have the potential to drastically reduce illness incidence by conferring immunity against the most frequent Leptospira serovars [11].

The focus on prevention is also shifting, with a greater emphasis on integrated approaches to controlling the environmental and ecological elements that contribute to leptospirosis transmission. An integrated strategy for outbreak prevention includes rodent management, immunization of high-risk groups, and the construction of effective surveillance systems. Furthermore, public health initiatives that educate communities on safe water practices and cleanliness, particularly in flood-prone areas with poor sanitation, are becoming increasingly important in global efforts to eradicate leptospirosis [12]. The purpose of this review is to provide a complete overview of developing developments in leptospirosis management and control. It will look at the most recent advances in diagnostic tools, therapeutic strategies, and preventive measures, and how these can help lessen the disease's global burden. By examining ongoing research and developments in these areas, the review will highlight the promising steps being taken to improve early detection, effective treatment, and prevention strategies, resulting in better health outcomes and reduced leptospirosis transmission worldwide.

1. Emerging Trends in Diagnosis

Accurate and prompt diagnosis is critical for effective leptospirosis care, as early detection of the infection can dramatically improve patient outcomes. Traditional diagnostic procedures, like as microscopy, culture, and serology, are still in use but have many limitations. These approaches frequently have low sensitivity, particularly during the early stages of infection, and necessitate specialist laboratory resources. Microscopy, for example, relies on finding Leptospira spirochetes in blood or urine samples, which can be difficult due to the bacteria's low abundance in the patient's body during the acute phase. Leptospira cultivation is time-consuming and can take many weeks to produce results. Serological methods, such as the microscopic agglutination test (MAT) and ELISA, while beneficial, may fail to identify antibodies in the early stages of the disease, delaying diagnosis [13-15]. However, recent advances in diagnostic technologies have increased the speed, sensitivity, and accuracy of leptospirosis identification. These developing trends show potential for more efficient diagnosis, particularly in areas with limited healthcare infrastructure or during outbreaks.

1.1. Molecular Diagnostics: PCR and qPCR

The polymerase chain reaction (PCR) has emerged as a key diagnostic tool for leptospirosis, providing greater sensitivity and specificity than previous approaches. PCR allows for the direct identification of Leptospira DNA in patient samples such as blood, urine, and cerebrospinal fluid, even in the early stages of infection when antibodies are not yet detectable. This molecular approach has considerably improved the ability to detect Leptospira early in the illness, allowing for earlier treatment and lowering the likelihood of serious results [16]. Quantitative PCR (qPCR), an enhanced variant of PCR, detects Leptospira DNA while also quantifying the bacterial load in the sample. This can provide valuable information regarding illness severity and aid in treatment decisions. Furthermore, qPCR can be used to track the progression of an infection or the efficacy of therapy, allowing healthcare providers to adapt treatment strategies more precisely [17].

1.2. Point-of-Care Diagnostic Tests: Lateral Flow Immunoassays (LFIAs)

Point-of-care diagnostic techniques, such as lateral flow immunoassays (LFIAs), have emerged as a valuable tool in the early identification of leptospirosis, particularly in resource-limited settings. These tests are easy, quick, and inexpensive, with results available within 15 to 20 minutes. They work by detecting antibodies or antigens in the patient's blood or urine and give a rapid technique to screen for Leptospira infection [18]. LFIAs have shown considerable potential in increasing the accessibility of leptospirosis diagnosis, particularly in

endemic locations where laboratory facilities may be limited. Their ease of use, portability, and low cost make them ideal for deployment in rural or isolated places where rapid diagnosis can improve treatment outcomes. Though LFIAs are not as sensitive as molecular approaches such as PCR, their ability to provide a preliminary diagnosis fast is a vital step in reducing leptospirosis transmission during outbreaks [19].

1.3. Serological Tests: Advancements in ELISA and Other Immunoassays

While classic serological tests, such as MAT [20], remain the gold standard for confirming leptospirosis, advances in immunoassay technologies have increased their usefulness. The enzyme-linked immunosorbent test (ELISA) has improved in terms of sensitivity and specificity, allowing for more reliable detection of antibodies to Leptospira antigens. ELISA tests are very useful for identifying leptospirosis in the late stages of infection because they can detect a spike in antibody levels, indicating recent exposure to the bacterium [21]. Furthermore, the development of multiplex serological assays capable of detecting numerous pathogens—such as dengue, malaria, and typhoid—has enhanced the capacity to distinguish leptospirosis from other infectious diseases with similar clinical presentations. These multiplex tests have demonstrated promise in expediting the diagnostic procedure in endemic areas where co-infection is widespread [22].

1.4. Next-Generation Sequencing (NGS)

Next-generation sequencing (NGS) is a new technology that enables the thorough genomic investigation of Leptospira strains. NGS facilitates the identification of new Leptospira species and variations, providing information about their genomic makeup and potential virulence factors [23]. While NGS is not now commonly employed in clinical diagnostics due to its high cost and complexity, it has enormous research potential and may play a role in future diagnostic advances. NGS can also be used to discover genetic markers linked to antimicrobial resistance (AMR), a growing concern in leptospirosis treatment. Identifying resistant Leptospira strains could lead to more targeted treatment tactics and the development of new drugs or alternative therapies. Furthermore, NGS may aid in the identification of biomarkers for the diagnosis and prognosis of leptospirosis, giving clinicians more reliable tools for assessing disease progression [14].

1.5. Molecular Typing and Epidemiological Surveillance

Another interesting breakthrough in leptospirosis diagnosis is the use of molecular type techniques like DNA sequencing and multi-locus sequence typing (MLST) to track the disease's prevalence. These methods allow for the identification of certain Leptospira strains and their correlation with specific outbreaks or geographic regions. Molecular typing, which links clinical isolates to environmental or animal reservoirs, can aid in identifying the most common sources of infection and guiding management methods [24]. In addition to enhancing individual diagnosis, molecular technologies can help public health officials discover trends, predict outbreaks, and conduct appropriate interventions.

1.6. Integrated Diagnostic Platforms

To improve the efficiency of leptospirosis diagnosis, researchers are creating integrated diagnostic platforms that combine different testing modalities (such as PCR, ELISA, and LFIAs) into a single system. These technologies can deliver quick, accurate results with minimal sample handling, enhancing diagnostic workflows in both clinical and field settings. Such integrated systems have the potential to provide a complete approach to diagnosing leptospirosis, particularly in distant or resource-constrained settings with limited laboratory capabilities [25]. This table 1 provides a clear summary of the diagnostic methods, their benefits, challenges, and where they are most useful in the context of leptospirosis management and outbreak control.

Table: 1 The emerging diagnostic trends in leptospirosis diagnosis

Diagnostic Method	Description	Advantages	Limitations	Applications	Ref
Molecular Diagnostics: PCR and qPCR	PCR detects Leptospira DNA directly from patient samples such as blood, urine, or cerebrospinal fluid. qPCR quantifies the bacterial load.	High sensitivity, early detection, quantification of bacterial load, enables monitoring of treatment efficacy.	Expensive, requires specialized equipment and trained personnel.	Early diagnosis in acute phases, monitoring infection progression, determining bacterial load.	[26]
Point-of-Care Diagnostic Tests: LFIAs	Lateral Flow Immunoassays detect antibodies or antigens in	Quick results (15-20 minutes), inexpensive, easy to	Lower sensitivity compared to molecular diagnostics,	Screening tool in endemic areas, rapid	[18]

	blood or urine. Provides rapid, portable results.	use, suitable for field settings and resource-limited areas.	not suitable for early detection in some cases.	preliminary diagnosis during outbreaks.	
Serological Tests: Advancements in ELISA	ELISA detects antibodies to Leptospira antigens in the blood. Improvements have enhanced sensitivity and specificity.	Reliable for late-stage detection, more specific than older serological methods.	Delayed antibody response (7-10 days), not useful for early-stage diagnosis.	Confirmation of diagnosis during later stages, distinguishing leptospirosis from other similar diseases. [14]
Next-Generation Sequencing (NGS)	Comprehensive genomic analysis of Leptospira strains, identifying genetic makeup and virulence factors.	Can detect new species, identify resistance markers, and study epidemiology and virulence.	Expensive, complex, not suitable for routine clinical diagnostics.	Research, identifying antimicrobial resistance, genomic epidemiology, future diagnostic improvements. [27]
Molecular Typing and Epidemiological Surveillance	Uses DNA sequencing and multi-locus sequence typing (MLST) to trace Leptospira strains and their geographic distribution.	Helps identify sources of infection, track outbreaks, and improve public health responses.	Requires significant resources and expertise, not a standard clinical tool.	Outbreak monitoring, epidemiological studies, improving public health response strategies. [28]
Integrated Diagnostic Platforms	Combines multiple diagnostic methods (PCR, ELISA, LFIAs) into one system for rapid, comprehensive testing.	Faster diagnosis, reduced sample handling, ideal for field settings.	Complex integration, requires technology investment.	Diagnostic tool for field and resource-constrained settings, multi-modal approach for better accuracy. [29]

2. Emerging Trends in Treatment

The primary treatment for leptospirosis is the use of antibiotics to eradicate Leptospira bacteria from the body. Early intervention is essential for avoiding consequences such liver failure, renal dysfunction, and hemorrhagic symptoms, which are frequently linked with severe forms of the disease. While antibiotics like doxycycline, penicillin, and ceftriaxone are widely used, there are still significant hurdles to optimizing the treatment regimen, particularly for severe infections and in light of rising concerns about antimicrobial resistance [30].

2.1. Standard Antibiotic Therapy and Its Limitations

The main antibiotic treatment for leptospirosis is either doxycycline or penicillin. Doxycycline is frequently favored because of its ability to target both Leptospira species and other co-infecting organisms, especially in endemic locations where many diseases may coexist [30]. Penicillin, on the other hand, is the preferred treatment for severe leptospirosis [31], particularly when there is a risk of meningitis or other systemic consequences. Ceftriaxone is an additional alternative for intravenous therapy in extreme situations, particularly for those who may not react to penicillin.

Despite the availability of these medicines, significant problems remain. To begin, antibiotics are most successful when used early in the course of infection, which can be problematic because leptospirosis is frequently misdiagnosed or missed, particularly in the mild or early stages [32]. Delayed therapy may result in more severe disease symptoms that necessitate more intense therapies. Second, there is increasing worry about antimicrobial resistance (AMR) in Leptospira species. While Leptospira has not yet shown widespread resistance to medicines, the establishment of resistant strains is a growing concern, especially with antibiotic overuse and misuse in both human and veterinary medicine [33].

2.2. Exploring New Antibiotics and Combination Therapies

In light of worries about AMR, research into novel antibiotics and combination therapy for leptospirosis has accelerated. Several research are looking into the efficacy of new antimicrobial drugs, such as extended-spectrum beta-lactams and other antibiotic families, which could offer an alternative to standard therapies in cases of resistance [34]. Another area of research is combination therapy, which uses antibiotics in conjunction with other supplemental therapies. For example, immunomodulatory drugs like corticosteroids or monoclonal antibodies may be used in conjunction with antibiotics to help manage the inflammatory response linked to severe leptospirosis. Systemic inflammation brought on by severe leptospirosis frequently results in additional tissue damage and organ failure. These adjuvant medicines seek to improve organ function, lower inflammation, and enhance overall therapeutic outcomes by modifying the immune response [35]. Some studies have also looked into the possible relevance of non-antibiotic medicines, such as antiviral drugs or immune system boosters, in supplementing antibiotics and improving recovery. Research into the use of immunotherapies, such as convalescent plasma from recovered people, is continuing. Convalescent plasma,

which contains antibodies to Leptospira, may help eliminate germs in the patient's body and increase the immune response, perhaps improving results in severe instances [36].

2.3. Antimicrobial Resistance (AMR) and Its Implications

Antimicrobial resistance (AMR) is a growing concern in the treatment of leptospirosis and other infectious illnesses. Although Leptospira has not yet shown widespread resistance, the increasing misuse of antibiotics in human and veterinary care enhances the possibility of resistance developing over time [37]. Furthermore, the emergence of resistance bacteria may make existing first-line antibiotics less effective, resulting in treatment failure and increased morbidity and mortality. The development of resistance in Leptospira may be especially alarming given the limited treatment options for severe patients. If antibiotics like doxycycline or penicillin become ineffective against resistant strains, it could lead to increased treatment costs, longer hospital stays, and more complicated clinical management [38]. As a result, antimicrobial stewardship initiatives, which attempt to maximize antibiotic use while minimizing resistance, will be critical in controlling leptospirosis in the future.

In response to the threat of AMR, researchers are investigating new classes of antibiotics that may be effective against *Leptospira*, including those that can target the bacteria's unique metabolic pathways or structural components [39]. Additionally, exploring natural products and plant-based antimicrobial compounds offers potential for discovering novel treatments with less likelihood of resistance development.

2.4. Adjunctive Therapies: Improving Patient Outcomes in Severe Cases

While antibiotics remain the cornerstone of treatment, severe instances of leptospirosis may necessitate further therapeutic intervention to address the disease's systemic consequences. To treat acute kidney injury, patients with significant renal impairment may require dialysis. Another common problem is respiratory failure, which may require mechanical ventilation and intensive care unit (ICU) assistance [40]. Beyond these supportive treatments, adjuvant medicines aiming at regulating the immune response are being investigated. Severe leptospirosis is distinguished by an overactive immune response, which causes extensive inflammation, endothelial damage, and multiorgan failure [41]. Corticosteroids have been explored for their ability to decrease this inflammatory response, with some studies indicating that they may lower mortality in severe cases. However, the use of steroids in leptospirosis remains contentious, and further research is needed to determine their function in treatment [42].

Monoclonal antibodies (mAbs), which can target specific immune response components or the bacteria itself, are another option for supplementary therapy. These biologics have shown promise in other infectious diseases and may provide a focused strategy to treating severe leptospirosis [43]. For example, mAbs that target inflammatory cytokines implicated in the disease's etiology may assist to reduce the overactive immune response and avoid organ damage.

2.5. Vaccine Development: A Long-Term Solution

Though leptospirosis vaccines are not yet available for people, researchers are actively working on them. Vaccines for cattle and pets are already in use in some areas, but no human vaccination has yet been approved. Researchers are investigating various techniques to eliciting protective immune responses against Leptospira, such as whole-cell vaccines, protein subunit vaccines, and DNA vaccines [44 & 45]. A human vaccination has the potential to significantly reduce the prevalence of leptospirosis, especially among high-risk populations such as agricultural laborers, military personnel, and those living in endemic areas. The development of a safe and effective vaccination could be a long-term option for reducing the global leptospirosis burden [46-48].

2.6. Personalized Medicine and Tailored Treatment Plans

Leptospirosis treatment options are becoming more individualized as genomic medicine advances. Understanding the genetic makeup of both the patient and the infecting Leptospira strain may allow healthcare practitioners to adjust antibiotic regimens and complementary therapy to the individual's specific needs. Furthermore, personalized medicine could aid in identifying individuals who are at a higher risk of developing severe disease, allowing for more proactive and targeted interventions [49]. This table 2 highlights the key emerging trends in leptospirosis treatment, emphasizing the need for improved diagnostic approaches, better antibiotic regimens, combination therapies, and innovations in vaccine development, all aimed at reducing the disease burden and improving patient outcomes.

Table: 2 The emerging trends in the treatment of leptospirosis

Aspect	Emerging Trends	Details	R
Standard Antibiotic Therapy	Doxycycline, Penicillin, Ceftriaxone	Doxycycline is chosen for mild to moderate instances, while penicillin is used for severe cases, particularly those involving meningitis or systemic problems. For severe cases, use ceftriaxone.	[38]
	Limitations	Delayed diagnosis or treatment can lead to poorer illness outcomes. Antibiotics are beneficial when given early, but misdiagnosis or delayed treatment worsens the condition.	
Antimicrobial Resistance (AMR)	Concerns of Resistance Development	Antibiotic abuse increases the risk of AMR. Resistance in Leptospira may make traditional treatments less effective, increasing treatment failure and morbidity.	[50]
	Antimicrobial Stewardship	Optimizing antibiotic use to prevent resistance. To combat AMR and prevent widespread treatment failure, researchers are looking for other antibiotics.	
New Antibiotics and Combination Therapies	New Antibiotics (Extended-Spectrum Beta-Lactams, etc.)	Investigating novel antibiotics to combat AMR. Extended-spectrum beta-lactams and other classes of antibiotics offer hope for alternative treatments.	[51]
	Combination Therapies	Antibiotic and immunomodulatory medications (such as corticosteroids and monoclonal antibodies) are used to treat both infection and immunological response. These may assist to reduce inflammation and enhance organ function.	
Adjunctive Therapies	Immunomodulatory Agents (Corticosteroids, Monoclonal Antibodies)	Corticosteroids and mAbs are being studied for their ability to alleviate systemic inflammation and organ damage, especially in severe cases. Further research is required to assess their effectiveness.	[52]
	Convalescent Plasma	Investigating the use of plasma from recovered patients to boost the immune response, neutralize bacteria, and improve outcomes in severe leptospirosis cases.	
Vaccine Development	Human Vaccine Development	Research is ongoing to develop a human vaccine against leptospirosis, with various strategies such as whole-cell, protein subunit, and DNA vaccines under investigation.	[53]
	Current Vaccines in Livestock and Pets	Existing vaccines for animals (livestock and pets) may assist to limit transmission in endemic areas, but no human vaccine has yet been approved.	
Personalized Medicine	Genomic Medicine	Treatment regimens are tailored based on the patient's genetic profile and the Leptospira strain that infects them. This could increase therapy efficacy and identify high-risk patients for severe illness.	[39]
Treatment for Severe Cases	Dialysis, Respiratory Support	For individuals with acute kidney injury or respiratory failure, dialysis and mechanical ventilation may be required to treat life-threatening consequences.	[41 & 42]

3.Emerging Trends in Leptospirosis Prevention

Leptospirosis, a bacterial infection spread through contact with water or soil contaminated by sick animals' urine, is a major public health concern globally. Preventing leptospirosis is critical, particularly in high-risk locations with frequent human-wildlife contact and insufficient sanitation. Emerging preventative trends emphasize integrated approaches that include environmental management, public health education, vaccination, and surveillance [54].

3.1. Environmental and Vector Control

Controlling rodent populations is critical in the prevention of leptospirosis since rodents are the principal reservoirs for the Leptospira bacteria that causes the illness. Infected rats release bacteria in their urine, which can contaminate the environment and pose a risk to humans through direct or indirect contact with contaminated water, soil, or surfaces. To reduce the likelihood of leptospirosis transmission, thorough environmental and vector management techniques are required. These solutions include improving sanitation, increasing public knowledge of safe waste disposal, and implementing effective rodent control programs [55]. One of the first measures in lowering the danger of leptospirosis is to improve sanitation, particularly in places where rodent populations thrive. Poor sanitation creates excellent circumstances for rodents to thrive, since rubbish, food leftovers, and carelessly stored waste attracts them. Promoting clean and safe settings reduces

the availability of food and shelter for rodents, which can assist lower their population. In both urban and rural regions, proper waste disposal systems and regular waste collection are critical to reducing rodent infestations [56]. Raising public knowledge is another important part of leptospirosis prevention. Many people may be unaware of the risks posed by rats or how leptospirosis spreads. Communities might benefit from education efforts that emphasize the necessity of avoiding contact with potentially polluted water sources, using protective gear when working in rodent-infested areas, and practicing good hygiene [57]. Public knowledge can also encourage people to report rodent sightings, allowing local authorities to act immediately with effective control measures.

Rodent management strategies are critical for minimizing the number of diseased rodents in the environment. These initiatives typically use a range of techniques to reduce rodent populations and restrict their access to human areas. Rodenticides, or chemical poisons, are one method of managing rodents. Rodenticides must be handled with caution since inappropriate application might contaminate the environment and kill non-target species [58]. When used strategically, rodenticides can be helpful in lowering rodent populations in regions with high infestations.

3.2. Vaccination of At-Risk Populations

Vaccination of at-risk populations is an important technique for avoiding leptospirosis, particularly in endemic areas. Farmers, veterinarians, military people, and laboratory professionals are especially vulnerable because they come into intimate contact with animals or places polluted with Leptospira bacteria [59]. Vaccinating these people reduces the spread of the disease and provides protection against prospective exposure. Currently current vaccinations are effective, but only protect against a subset of Leptospira serovars. Because there are so many Leptospira serovars, finding vaccines that target a wider variety of these strains is a top objective. Researchers are working to develop safer, more effective vaccinations with longer-lasting protection and fewer adverse effects. This development is difficult due to the complexity of Leptospira and its tendency to vary by place [53]. While vaccination is an effective preventive measure, it should be used in conjunction with other techniques such as rodent control, sanitary improvements, and public health education. These approaches work jointly to limit bacteria exposure while also improving the vaccine's protective impact.

3.3. Personal Protective Measures

Individuals operating in high-risk areas for leptospirosis, such as agriculture workers, sewage workers, and military personnel, must take personal protective precautions. These people have a higher risk of coming into touch with Leptospira bacteria, which can be found in contaminated water, soil, or animal urine. To lower the danger of infection, it is critical to implement preventative measures that limit exposure [53]. Wearing suitable protective clothes is an important personal safety precaution. This includes long-sleeved clothing, pants, gloves, and boots to avoid direct contact with contaminated surfaces. When working with animals, soil, or water that may have been contaminated with rodent urine or other potential sources of Leptospira, wear gloves. Boots are also necessary to protect the feet from contamination, especially in regions where standing water might house bacteria [60]. Individuals should also cover any open wounds or injuries with waterproof bandages or dressings to avoid contact with polluted water or dirt. Since Leptospira can enter the body through skin cracks, dressing wounds is a simple yet efficient technique to reduce the risk of infection. It is also critical to avoid contact with potentially polluted water sources, such as rivers, lakes, or puddles where rodents and other animals have urinated [61 & 62].

3.4. Surveillance and Early Detection

Surveillance and early detection are critical for reducing the spread of leptospirosis, especially in places where the disease is endemic or outbreaks occur often. Effective surveillance systems allow health officials to detect leptospirosis cases early, monitor disease trends, and prevent further transmission [63]. By monitoring illness incidence, these systems can identify potential hotspots, allowing for targeted interventions before the outbreak expands. Improved surveillance enables the identification of critical risk variables linked to leptospirosis outbreaks, such as specific environmental conditions, geographic regions, or high-risk groups. By assessing these variables, health organizations may create more targeted prevention measures and distribute resources more efficiently [46]. This preventative strategy can help reduce the number of cases and keep the disease from spreading.

Integrating geographical data with disease monitoring improves the ability to track leptospirosis in real time. Health officials can anticipate and respond quickly to possible epidemics by mapping disease cases and linking them with environmental factors such as rainfall, rodent populations, and sanitary conditions [49 & 64]. Geospatial tools can enable more effective intervention planning in high-risk areas, ensuring that preventive actions like rodent control or vaccination programs are performed where they are most required.

3.5. Public Health Education

Public health education is an essential component in avoiding leptospirosis, particularly in locations where the disease is more widespread. Education campaigns can induce anti-infective behaviours by alerting the public about the hazards and transmission channels of Leptospira bacteria. One of the primary goals of these initiatives is to promote good sanitation and hygiene habits [57 & 65]. Educating populations on the need of keeping clean environments, proper waste disposal, and avoiding contact with contaminated water sources can greatly minimize the risk of exposure to microorganisms. In addition to general public education, care should be taken to avoid contact with possibly polluted water, which may include infectious rodent and animal urine. This is especially true in rural or flood-prone locations, where people may come into touch with standing water [66]. Public health campaigns can encourage people to wear protective gear like boots and gloves, especially when working in places where contamination is likely. Equally crucial is training healthcare personnel about leptospirosis detection and treatment. Timely diagnosis and adequate medical management are crucial in lowering the disease's morbidity and death. Training healthcare personnel to recognize leptospirosis symptoms and risk factors helps that patients receive timely and appropriate care, which can lead to better results.

Conclusion

Leptospirosis is a major global health threat, particularly in tropical and subtropical countries. Advances in molecular diagnostics, such as PCR and real-time assays, have made it easier to detect the infection in its early stages, allowing for timely treatment. Antibiotics remain the primary treatment, but research into immunotherapy, vaccines, and combination medicines gives hope for better outcomes in severe cases. Preventive interventions, such as rodent control, immunization of vulnerable populations, and public health education, are critical components of leptospirosis management. The global burden of leptospirosis can be greatly decreased in the next years by implementing a multifaceted approach that includes improved diagnostic tools, innovative therapies, and expanded preventative initiatives.

Financial support and sponsorship

None

Conflicts of interest

There are no conflicts of interest.

References

1. Fraga TR, Carvalho E, Isaac L, Barbosa AS. Leptospira and leptospirosis. InMolecular medical microbiology 2024 Jan 1 (pp. 1849-1871). Academic Press.
2. Rodríguez-Rodriguez VC, Castro AM, Soto-Florez R, Urango-Gallego L, Calderón-Rangel A, Agudelo-Flórez P, Monroy FP. Evaluation of serological tests for different disease stages of leptospirosis infection in humans. Tropical Medicine and Infectious Disease. 2024 Nov 20;9(11):283.
3. Liu YH, Chen YH, Chen CM. Fulminant Leptospirosis Presenting with Rapidly Developing Acute Renal Failure and Multiorgan Failure. Biomedicines. 2024 Feb 15;12(2):435.
4. Allyn J, Miailhe AF, Delmas B, Marti L, Allou N, Jabot J, Reignier J. Severe leptospirosis in tropical and non-tropical areas: A comparison of two french, multicentre, retrospective cohorts. PLOS Neglected Tropical Diseases. 2024 Apr 10;18(4):e0012084.
5. Zhang L, Guo W, Lv C. Modern technologies and solutions to enhance surveillance and response systems for emerging zoonotic diseases. Science in One Health. 2024 Jan 1;3:100061.
6. Win TZ, Han SM, Edwards T, Maung HT, Brett-Major DM, Smith C, Lee N. Antibiotics for treatment of leptospirosis. Cochrane Database of Systematic Reviews. 2024(3).
7. de Jong HK, Grobusch MP. Monoclonal antibody applications in travel medicine. Tropical Diseases, Travel Medicine and Vaccines. 2024 Jan 15;10(1):2.
8. Jayathangaraj MG, Raman M, Charitha BB, Gollu C, Sri BD. Review on Leptospirosis in Animals and Associated One Health Concept. The Indian Veterinary Journal. 2024 Nov;101(11):7-14.
9. Pal M, Tariku F, Upadhyay D, Zende R. Current innovations in the diagnosis and immunization of emerging and reemerging zoonoses. American Journal of Epidemiology and Infectious Disease. 2024;12(2):23-8.
10. Rana T, Sarwar A, Mahmood A, Batool N, Shamim R, Gul S, Arshad I, Iftikhar F, Ali A, Sarwar F. Molecular Techniques Used for Diagnosis of Zoonotic Diseases. Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan. 2023;1:388-99.

11. Barazzone GC, Teixeira AF, Azevedo BO, Damiano DK, Oliveira MP, Nascimento AL, Lopes AP. Revisiting the development of vaccines against pathogenic Leptospira: innovative approaches, present challenges, and future perspectives. Frontiers in Immunology. 2022 Jan 3;12:760291.

12. Acosta-España JD, Romero-Alvarez D, Luna C, Rodriguez-Morales AJ. Infectious disease outbreaks in the wake of natural flood disasters: Global patterns and local implications. Le Infezioni in Medicina. 2024 Dec 1;32(4):451.

13. Pinto GV, Senthilkumar K, Rai P, Kabekkodu SP, Karunasagar I, Kumar BK. Current methods for the diagnosis of leptospirosis: Issues and challenges. Journal of Microbiological Methods. 2022 Apr 1;195:106438.

14. Sykes JE, Reagan KL, Nally JE, Galloway RL, Haake DA. Role of diagnostics in epidemiology, management, surveillance, and control of leptospirosis. Pathogens. 2022 Mar 24;11(4):395.

15. Hwee SE, Htet NH, Naing C, Tung WS, Mak JW. Rapid diagnostic test (Leptocheck-WB) for detection of acute leptospirosis: a meta-analysis of diagnostic accuracy. European Journal of Clinical Microbiology & Infectious Diseases. 2022 Apr;41(4):631-40.

16. Pal M, Lema AG, Atalel D. Immunological and molecular diagnostic techniques for leptospirosis: an update. Int J Clin Exp Med Res. 2022;6:216-.

17. Lam JY, Low GK, Chee HY. Diagnostic accuracy of genetic markers and nucleic acid techniques for the detection of Leptospira in clinical samples: A meta-analysis. PLoS neglected tropical diseases. 2020 Feb 12;14(2):e0008074.

18. Pujato N, Gimenez JM, Peretti LE, Landolt NY, Jacob P, Chiani YT, Schmeling MF, Miraballes I, Vanasco NB. Development of a new accurate lateral flow immunoassay for diagnosis of human leptospirosis. European Journal of Clinical Microbiology & Infectious Diseases. 2024 Oct;43(10):1959-68.

19. Nan X, Yao X, Yang L, Cui Y. Lateral flow assay of pathogenic viruses and bacteria in healthcare. Analyst. 2023;148(19):4573-90.

20. Romero-Vivas CM, Cuello-Pérez M, Falconar AK. Dengue virus infected patients can generate false positives in the 'gold standard'Leptospira spp. microscopic agglutination test (MAT), immunofluorescence assays (IFAs), and immunoblot assays due to cross-reactive IgG and/or IgM antibodies against their outer surface membrane proteins. medRxiv. 2023 Mar 16:2023-03.

21. Cariou C, Herbet G, Ripart P, Martin-Cagnon N, Bouvet J, Schneider M, Guiot AL, Cupillard L. Development of antibody ELISA specific of Leptospira interrogans serovar Grippotyphosa, Canicola, and Icterohaemorrhagiae to monitor vaccine immunogenicity. Veterinary immunology and immunopathology. 2020 Jan 1;219:109960.

22. Samrot AV, Sean TC, Bhavya KS, Sahithya CS, Chan-Drasekaran S, Palanisamy R, Robinson ER, Subbiah SK, Mok PL. Leptospiral infection, pathogenesis and its diagnosis—A review. Pathogens. 2021 Feb 1;10(2):145.

23. Grillova L, Cokelaer T, Mariet JF, Da Fonseca JP, Picardeau M. Core genome sequencing and genotyping of Leptospira interrogans in clinical samples by target capture sequencing. BMC Infectious Diseases. 2023 Mar 14;23(1):157.

24. Caimi K, Ruybal P. Leptospira spp., a genus in the stage of diversity and genomic data expansion. Infection, Genetics and Evolution. 2020 Jul 1;81:104241.

25. Verma V, Goyal M, Kala D, Gupta S, Kumar D, Kaushal A. Recent advances in the diagnosis of leptospirosis. Frontiers in Bioscience-Landmark. 2020 Mar 1;25(9):1655-81.

26. Gayathri R, Archana V, Ramya M. Molecular Diagnostic Methods for the Detection of Leptospirosis. Journal of Pure & Applied Microbiology. 2022 Jun 1;16(2).

27. Jiang X, Jiang H, Xiong Y, Fang M, Geng B, Wu H, Mei X. Early diagnosis by mNGS could improve the prognosis for severe leptospirosis patients.

28. Mendoza MV, Rivera WL. Application of simplified MLST scheme for direct typing of clinical samples from human leptospirosis cases in a tertiary hospital in the Philippines. PLoS One. 2021 Oct 20;16(10):e0258891.

29. Deroco PB, Junior DW, Kubota LT. Recent advances in point-of-care biosensors for the diagnosis of neglected tropical diseases. Sensors and actuators B: chemical. 2021 Dec 15;349:130821.

30. Chancharoenthana W, Leelahavanichkul A, Schultz MJ, Dondorp AM. Going micro in leptospirosis kidney disease. Cells. 2022 Feb 16;11(4):698.

31. Guzmán Pérez M, Blanch Sancho JJ, Segura Luque JC, Mateos Rodriguez F, Martínez Alfaro E, Solís García del Pozo J. Current evidence on the antimicrobial treatment and chemoprophylaxis of human leptospirosis: a meta-analysis. Pathogens. 2021 Sep 2;10(9):1125.

32. Fraga TR, Carvalho E, Isaac L, Barbosa AS. Leptospira and leptospirosis. InMolecular medical microbiology 2024 Jan 1 (pp. 1849-1871). Academic Press.

33. Choudhary S, Choudhary RK, Kumar M, Singh S, Malik YS. Epidemiological Status of Leptospirosis in India. Journal of Pure & Applied Microbiology. 2023 Dec 1;17(4).

34. Hardefeldt LY, Prescott JF. Beta-lactam Antibiotics: Cephalosporins. Antimicrobial Therapy in Veterinary Medicine. 2024 Dec 30:143-67.

35. Paz LN, Dias CS, Almeida DS, Balassiano IT, Medeiros MA, Costa F, Silva DN, Reis JN, Estrela-Lima A, Hamond C, Pinna MH. Multidisciplinary approach in the diagnosis of acute leptospirosis in dogs naturally infected by Leptospira interrogans serogroup Icterohaemorrhagiae: A prospective study. Comparative Immunology, Microbiology and Infectious Diseases. 2021 Aug 1;77:101664.

36. Petakh P, Oksenych V, Kamyshnyi O. Corticosteroid Treatment for Leptospirosis: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2024 Jul 24;13(15):4310.

37. Petakh P, Kamyshnyi O. AMR mechanisms in L. interrogans serovars: a comprehensive study. Frontiers in Cellular and Infection Microbiology. 2024 Apr 11;14:1384427.

38. Septelici D, Carbone G, Cipri A, Esposito S. Management Strategies for Common Animal Bites in Pediatrics: A Narrative Review on the Latest Progress. Microorganisms. 2024 May 1;12(5):924.

39. Petakh P, Behzadi P, Oksenych V, Kamyshnyi O. Current treatment options for leptospirosis: a mini-review. Frontiers in Microbiology. 2024 Apr 25;15:1403765.

40. Daschner C, Schübler AS, Jung M, Ayasse N, Yücel G, Husain-Syed F, Leipe J, Krämer BK, Yazdani B. Severe Leptospirosis with Acute Kidney Injury: A Case Description and Literature Review. Nephron. 2024 Dec 16;148(11-12):832-9.

41. Liu YH, Chen YH, Chen CM. Fulminant Leptospirosis Presenting with Rapidly Developing Acute Renal Failure and Multiorgan Failure. Biomedicines. 2024 Feb 15;12(2):435.

42. Smith S, Liu YH, Carter A, Kennedy BJ, Dermedgoglou A, Poulgrain SS, Paavola MP, Minto TL, Luc M, Hanson J. Severe leptospirosis in tropical Australia: Optimising intensive care unit management to reduce mortality. PLoS neglected tropical diseases. 2019 Dec 2;13(12):e0007929.

43. Cariou C, Herbet G, Ripart P, Martin-Cagnon N, Bouvet J, Schneider M, Guiot AL, Cupillard L. Development of antibody ELISA specific of Leptospira interrogans serovar Grippotyphosa, Canicola, and Icterohaemorrhagiae to monitor vaccine immunogenicity. Veterinary immunology and immunopathology. 2020 Jan 1;219:109960.

44. Esteves SB, Santos CM, Salgado FF, Goncales AP, Guilloux AG, Martins CM, Hagiwara MK, Miotto BA. Efficacy of commercially available vaccines against canine leptospirosis: A systematic review and meta-analysis. Vaccine. 2022 Mar 15;40(12):1722-40.

45. Azevedo IR, Amamura TA, Isaac L. Human leptospirosis: In search for a better vaccine. Scandinavian Journal of Immunology. 2023 Nov;98(5):e13316.

46. Bradley EA, Lockaby G. Leptospirosis and the environment: A review and future directions. Pathogens. 2023 Sep 16;12(9):1167.

47. Khairullah AR, Kusala MK, Fauziah I, Furqoni AH, Suhendro I, Effendi MH, Raissa R, Moses IB, Silaen OS, Yuliatun L, Yanestria SM. Deciphering leptospirosis: Insights into an emerging global threat. Journal of Advanced Veterinary Research. 2024 Jul 13;14(6):1065-71.

48. Haake DA, Galloway RL. Leptospiral infections in humans. Clinical Microbiology Newsletter. 2021 Oct 15;43(20):173-80.

49. Antima, Banerjee S. Modeling the dynamics of leptospirosis in India. Scientific Reports. 2023 Nov 13;13(1):19791.

50. Nisansala GG, Weerasekera M, Ranasinghe N, Gamage C, Marasinghe C, Fernando N, Gunasekara C. Predictors of Severe Leptospirosis on Admission: A Sri Lankan Study. International Journal of Infectious Diseases. 2023 Aug 1;134:S18-9.

51. Christie SA, Hariharan S, Chakraborti S, Srinivasan N, Madanan MG. A New Beginning to the Existing Medicines; Repurposing FDA-Approved Drugs for the Neglected Re-Emerging Disease Leptospirosis. ACS omega. 2024 Jul 22;9(30):32717-26.

52. Miklaušić Pavić B. Adjunctive treatment of leptospirosis with corticosteroids: a case report. Infektološki glasnik. 2019;39(2):50-3.

53. Felix CR, Siedler BS, Barbosa LN, Timm GR, McFadden J, McBride AJ. An overview of human leptospirosis vaccine design and future perspectives. Expert opinion on drug discovery. 2020 Feb 1;15(2):179-88.

54. Gupta N, Wilson W, Ravindra P. Leptospirosis in India: a systematic review and meta-analysis of clinical profile, treatment and outcomes. Le Infezioni in Medicina. 2023;31(3):290.

55. Antima, Banerjee S. Modeling the dynamics of leptospirosis in India. Scientific Reports. 2023 Nov 13;13(1):19791.

56. Aboyitungiye JB, Gravitiani E. River pollution and human health risks: Assessment in the locality areas proximity of Bengawan Solo river, Surakarta, Indonesia. Indonesian Journal of Environmental Management and Sustainability. 2021 Mar 12;5(1):13-20.

57. Beri D, Moola S, Jagnoor J, Salam A, Bhaumik S. Prevention, control and management of leptospirosis in India: an evidence gap map. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2021 Dec;115(12):1353-61.

58. Meerburg BG. Public health and rodents: a game of cat and mouse. InZoonoses: Infections Affecting Humans and Animals 2022 Oct 27 (pp. 1-14). Cham: Springer International Publishing.

59. Salman M, Steneroden K. Important Zoonotic Diseases of Cattle and Their Prevention Measures. InZoonoses: Infections Affecting Humans and Animals 2022 Oct 15 (pp. 1-22). Cham: Springer International Publishing.

60. Ghasemian A, Abbas AF, Al-Saadi AG, Salari M, Memariani H, Mostafavi SK. Occupational leptospirosis as an underreported disease in high-risk groups: Implications for prevention and control measures. Reviews and Research in Medical Microbiology. 2020 Apr 1;31(2):75-8.

61. Porusia M, Andari AF, Wulandari W, Chotklang D. Risk factors of leptospirosis incidence in agricultural area. International Journal of Public Health Science. 2021 Sep;10(3):574-80.

62. Baharom M, Ahmad N, Hod R, Ja'afar MH, Arsad FS, Tangang F, Ismail R, Mohamed N, Radi MF, Osman Y. Environmental and occupational factors associated with leptospirosis: a systematic review. Heliyon. 2024 Jan 15;10(1).

63. Soo ZM, Khan NA, Siddiqui R. Leptospirosis: Increasing importance in developing countries. Acta tropica. 2020 Jan 1;201:105183.

64. Moola S, Beri D, Salam A, Jagnoor J, Teja A, Bhaumik S. Leptospirosis prevalence and risk factors in India: Evidence gap maps. Tropical Doctor. 2021 Jul;51(3):415-21.

65. Fatema A, Ramu M, Thiruvengadam K, Sunish IP, Vijayachari P. Knowledge, attitude, and preventive practices of leptospirosis affected populations in South Andaman, India: A cross-sectional study. Journal of Health Sciences. 2023 Sep 30;13(2):105-12.

66. Krishnan BK, Balasubramanian G, Kumar PP. Leptospirosis in India: insights on circulating serovars, research lacunae and proposed strategies to control through one health approach. One Health Outlook. 2024;6.